Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunomodulators

An amino acid, selected technology, applied in the direction of immunoglobulin, anti-blood group antigen immunoglobulin, anti-animal/human immunoglobulin, etc., can solve the problems of delayed disease development, unsatisfactory side effects of treatment, etc.

Inactive Publication Date: 2005-08-31
STEENO RES GROUP
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Said treatment is usually unsatisfactory, produces unwanted and often serious side effects, and merely delays rather than prevents disease progression

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunomodulators
  • Immunomodulators
  • Immunomodulators

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0181] Embodiment: 1.NH 2 -Ala-Tyr-Met-Thr- Ile -Lys- met -Arg-Asn-COOH (SEQ ID NO: 2)

[0182] 2. NH 2 -Ala- Phe -Met-Thr- Leu -Lys- Leu -Arg-Asn-COOH (SEQ ID NO: 3)

[0183] 3. NH 2 -Ala-Tyr-Met-Thr-Met-Lys- Val -Arg- Glu -COOH (SEQ ID NO: 4)

[0184] 4. NH 2 -Gly-Tyr-Met-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO: 5)

[0185] 5. NH 2 -Ala-Phe-Met-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO: 6)

[0186] 6. NH 2 -Ala-Tyr-Ile-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO: 7)

[0187] 7. NH 2 -Ala-Tyr-Leu-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO: 8)

[0188] 8. NH 2 -Ala-Tyr-Val-Thr-Met-Lys-Ile-Arg-Asp-COOH (SEQ ID NO: 9)

[0189] 9. NH 2 -Ala-Tyr-Met-Thr-Ile-Lys-Ile-Arg-Asp-COOH (SEQ ID NO: 10)

[0190] 10. NH 2 -Ala-Tyr-Met-Thr-Leu-Lys-Ile-Arg-Asp-COOH (SEQ ID NO: 11)

[0191] 11. NH 2 -Ala-Tyr-Met-Thr-Val-Lys-Ile-Arg-Asp-COOH (SEQ ID NO: 12)

[0192] 12. NH 2 -Ala-Tyr-Me...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to a polypeptide other than human interleukin (10) which has at least one of the following properties: a) induces inhibition of spontaneous IL-8 production by human monocytes, b) induces inhibition of IL-1 beta induced IL-8 production by human peripheral blood mononuclear cells (PBMC), c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes, d) induces chemotactic migration of CD8+ human T lymphocytes in vitro, e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10, f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8, g) suppresses the chemotactic response of human monocytes towards MCAF / MCP-1, h) does not inhibit class II MHC molecule expression on human monocytes, in contrast to human IL-10, i) induces the production of IL-4 by cultured normal human CD4+ T cells, j) reduces the TNF alpha production in human mixed leukocyte reaction. In particular, the invention relates to the nonapeptide Ala-Tyr-Met-Thr-Met-Lys-Ile-Arg-Asn and analogues and variants thereof.

Description

field of invention [0001] The present invention relates to a pharmaceutical use of a substance which is an interleukin 10 (IL-10) agonist, in particular to the use of the substance of the present invention in the preparation of a pharmaceutical composition for preventing and / or treating diseases, wherein the pathogenesis involves Reduced production and / or decreased function of immunosuppressive mediators, especially cytokines, and / or involvement of specific immune-inflammatory mediators, especially increased production and / or enhanced function of cytokines. In particular, the present invention relates to the use of the substances of the present invention in the preparation of pharmaceutical compositions for the prevention and / or treatment of autoimmune diseases (type I diabetes; gastrointestinal inflammatory diseases, rheumatoid arthritis), gout Acute (urica) arthritis (gout), skin allergies; skin, lung, and respiratory allergies (including bronchial asthma); tissue damage by ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/09A61K38/00A61K38/20A61K39/00A61K39/395A61P31/12A61P35/00A61P37/02A61P37/04A61P43/00C07K7/00C07K7/06C07K14/52C07K14/54C07K16/00C07K16/24C12N15/00C12N15/24C12P21/08C12R1/91
CPCA61K38/00C07K14/5428A61K39/00A61P31/12A61P35/00A61P37/02A61P37/04A61P43/00
Inventor C·格龙霍拉森B·杰泽
Owner STEENO RES GROUP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com